 |
|
|
| |
Drug Use and Reinfection Following HCV Treatment With
Elbasvir/Grazoprevir Among Patients Receiving Opioid
Agonist Therapy: Final Results From the CO-STAR Study
|
| |
| |
AASLD 2019 Nov 8-11 Boston
Reported by Jules Levin
Jason Grebely1; Brian Conway2; Alain H. Litwin3; Olav Dalgard4; Oren Shibolet5; Ronald Nahass6; Frederick Altice7;
Edward J. Gane8; Anne Luetkemeyer9; Cheng-Yuan Peng10; David Iser11; Isaias Noel Gendrano12; Michelle M. Kelly12;
Peggy Hwang12; Ernest Asante-Appiah12; Eliav Barr12; Michael N. Robertson12; Heather Platt12; Gregory J. Dore1
1The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; 2Vancouver Infectious Diseases Centre, Vancouver, BC, Canada; 3Albert
Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA; 4Institute of Clinical Medicine, Akershus University, Oslo, Norway;
5Liver Unit, Department of Gastroenterology, Tel Aviv Medical Center and Tel Aviv University, Tel Aviv, Israel; 6ID Care, Hillsborough, NJ, USA;
7Yale University, New Haven, CT, USA; 8Auckland City Hospital, Auckland, New Zealand; 9University of California, San Francisco, San
Francisco, CA, USA; 10China Medical University Hospital, Taichung, Taiwan; 11The Alfred Hospital, Melbourne, VIC, Australia; 12Merck & Co.,
Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
